Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (6044)	3/27/2002 11:15:29 AM
From: Biomaven	Read Replies (5) \| Respond to of 52153

quid, Current market cap is $1.3 billion. Natrecor is a very tricky drug to value, mainly because it's not clear just how widely it will be adopted. Forecast 2002 sales are in the $55m to $60m range, up very sharply from FY00's $14m (launch was about mid-year). I would expect them to beat that estimate, based on how quickly they have already gained traction. (It helps some that they aren't competing with drugs that are being actively detailed, but it hurts that they don't have a real pharma partner in the US). They pay a declining royalty through 2008 to their marketing partner (QTRN's Innovex). There are about a million admissions for acute CHF each year. There are also a substantial number of patients (one estimate I saw was 80k) that are at home but always on the verge of acute CHF. These could potentially receive (perhaps) weekly therapy at home, which would dramatically increase the market for the drug. So at one extreme the drug could eventually become a billion dollar blockbuster. Alternatively, sales could stall at much lower levels - perhaps $200m, or comparable to Milrinone. A lot will depend on how their post-marketing trials go and how the drug is perceived as working in real life. If you take the conservative $200m eventual peak sales view, then SCIO is likely already fairly valued at these prices (assuming your posited failure of their P-38 program). If you take the blockbuster view, then the stock likely is still a potential 5-bagger, assuming it isn't acquired first. (The CEO has multiple myeloma). Peter